GERN · XBRL financial data
Geron financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (GERN's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 0* | 0 | 1 | 28 | — | 40 | 49 | 47 | — | 52 | 57 |
| Selling, general and administrative | 18 | 21* | 27 | 39 | 36 | 43* | 40 | 39 | 39 | 42* | 35 | 39 |
| General and administrative | 18 | 21* | 27 | — | — | — | — | — | — | — | — | — |
| Total operating expenses | 48 | 54* | 56 | 70 | 56 | 68* | 56 | 61 | 61 | 74* | 52 | 70 |
| Operating income (loss) | (48) | (54)* | (56) | (69) | (28) | (20)* | (17) | (12) | (14) | (26)* | 0 | (12) |
| Interest income | 5 | 5* | 4 | 5 | 5 | 5* | 5 | 5 | 4 | 4* | 3 | 3 |
| Interest expense | 2 | 2* | 3 | 3 | 3 | 9* | 8 | 9 | 9 | 7* | 7 | 7 |
| Other income (expense) | (0) | 0* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) |
| Income tax expense (benefit) | — | year only | — | — | — | year only | — | — | — | year only | — | — |
| Net income (loss) | (45) | (52)* | (55) | (67) | (26) | (25)* | (20) | (16) | (18) | (29)* | (4) | (17) |
| Earnings per share, basic USD per share | (0.08) | (0.09)* | (0.09) | (0.10) | (0.04) | (0.04)* | (0.03) | (0.02) | (0.03) | (0.04)* | (0.01) | (0.02) |
| Earnings per share, diluted USD per share | (0.08) | (0.09)* | (0.09) | (0.10) | (0.04) | (0.04)* | (0.03) | (0.02) | (0.03) | (0.04)* | (0.01) | (0.02) |
| Weighted average shares, basic millions of shares | 580 | 611* | 603 | 654 | 662 | 664* | 666 | 666 | 667 | 667* | 1 | 1 |
| Weighted average shares, diluted millions of shares | 580 | 611* | 603 | 654 | 662 | 664* | 666 | 666 | 667 | 667* | 1 | 1 |
Balance sheet
CSVFiscal quarters (GERN's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 31 | 70 | 190 | 117 | 60 | 79 | 84 | 78 | 78 | 78 | 69 | 63 |
| Marketable securities | 283 | 264 | 253 | 246 | 279 | 328 | — | — | — | — | — | — |
| Marketable securities, non-current | 68 | 43 | 21 | 67 | 37 | 95 | — | — | — | — | — | — |
| Accounts receivable | — | — | — | 1 | 28 | 36 | 31 | 37 | 35 | 37 | 42 | 52 |
| Inventory | — | — | — | 1 | 20 | 39 | 56 | 69 | 95 | 117 | 133 | 124 |
| Prepaid and other current assets | 6 | 5 | 6 | 6 | 6 | 5 | 7 | 7 | 7 | 5 | 7 | 6 |
| Total current assets | 335 | 341 | 452 | 373 | 398 | 491 | 496 | 506 | 522 | 520 | 499 | 486 |
| Property and equipment, net | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Right-of-use asset | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 |
| Total assets | 413 | 394 | 482 | 449 | 445 | 594 | 562 | 555 | 567 | 571 | 534 | 519 |
| Accounts payable | 14 | 6 | 10 | 6 | 14 | 9 | 8 | 8 | 11 | 11 | 13 | 9 |
| Accrued liabilities | 42 | 40 | 34 | 39 | 36 | 36 | 29 | 26 | 40 | 51 | 31 | 31 |
| Current portion of long-term debt | 22 | 47 | 72 | 47 | 72 | — | — | — | — | — | — | — |
| Total current liabilities | 89 | 108 | 123 | 104 | 138 | 88 | 63 | 64 | 88 | 112 | 74 | 70 |
| Long-term debt | 30 | 35 | 11 | 37 | 12 | 118 | 119 | 119 | 119 | 120 | 120 | 120 |
| Lease liability, non-current | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Total liabilities | — | 146 | — | — | — | 313 | — | — | — | 345 | 305 | 300 |
| Accumulated deficit | (1,546) | (1,598) | (1,653) | (1,721) | (1,747) | (1,772) | (1,792) | (1,809) | (1,827) | (1,856) | (1,859) | (1,876) |
| Total stockholders' equity | 291 | 248 | 345 | 307 | 292 | 280 | 268 | 260 | 249 | 226 | 229 | 219 |
| Total liabilities and equity | 413 | 394 | 482 | 449 | 445 | 594 | 562 | 555 | 567 | 571 | 534 | 519 |
| Common shares outstanding (cover page) millions of shares | 543 | 546 | 593 | 603 | 605 | 637 | 637 | 638 | 638 | 641 | 642 | 642 |
Cash flows
CSVFiscal quarters (GERN's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (45) | (52)* | (55) | (67) | (26) | (25)* | (20) | (16) | (18) | (29)* | (4) | (17) |
| Stock-based compensation | 7* | 4* | 5 | 13* | 7* | 7* | 7 | 7* | 7* | 6* | 5 | 5* |
| Net cash from operating activities | (51)* | (41)* | (62) | (53)* | (59)* | (44)* | (48) | (27)* | (14)* | (22)* | (63) | (16)* |
| Purchases of property and equipment | 0* | 0* | 1 | 0* | 0* | (0)* | — | — | — | — | — | — |
| Net cash from investing activities | (5)* | 48* | 34 | (36)* | (1)* | (104)* | 52 | 20* | 13* | 21* | 52 | 8* |
| Proceeds from long-term debt | — | year only | — | — | — | year only | — | — | — | year only | — | — |
| Repayments of long-term debt | — | year only | — | — | — | year only | — | — | — | year only | — | — |
| Net cash from financing activities | 29* | 33* | 148 | 17* | 4* | 166* | 0 | 1* | 1* | 0* | 2 | 1* |
| Net change in cash | (26)* | 40* | 120 | (73)* | (56)* | 19* | 5 | (6)* | 0* | (1)* | (9) | (6)* |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Geron | 63 | 57 | (16)* | 642.5M | 4.0 quarters | 10-QJun 30, 2026 |
| Intellia Therapeutics | 106 | 7.7 | (83)* | 140.1M | 5.3 quarters | 10-QJun 30, 2026 |
| Wave Life Sciences | 197 | 13 | (60)* | 197.2M | 7.4 quarters | 10-QSep 30, 2026 |
| CorMedix | 257 | 102 | 86* | 77.9M | — | 10-QJun 30, 2026 |
| Niagen Bioscience | 67 | 30 | 2.8* | 79.1M | — | 10-QJun 30, 2026 |
| Nurix Therapeutics | 720 | 673 | 616* | 109.2M | — | 10-QAug 31, 2026 |
| Ardelyx | 46 | 128 | 2.2* | 251.4M | — | 10-QSep 30, 2026 |
| Collegium Pharmaceutical | 129 | 200 | 71* | 32.6M | — | 10-QJun 30, 2026 |
| Syndax Pharmaceuticals | 136 | 83 | (27)* | not reported | 11.9 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.